Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis
- PMID: 17599726
- DOI: 10.1002/art.22718
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis
Abstract
Objective: To evaluate the efficacy of infliximab plus methotrexate (MTX) as induction therapy in patients with early rheumatoid arthritis (RA).
Methods: Disease-modifying antirheumatic drug (DMARD)-naive patients with active, early RA who were included as group 4 of the BeSt study were initially treated with infliximab (3 mg/kg) in combination with MTX (25 mg/week). The Disease Activity Score (DAS) was measured every 3 months. In patients with persistent low disease activity (DAS <or=2.4) for at least 6 months, the infliximab dosage was tapered and finally discontinued; the MTX dosage then was tapered to 10 mg/week. In patients with a DAS of >2.4, the infliximab dosage was increased (maximum 10 mg/kg), and they were subsequently switched to another DMARD. Except for intraarticular administration, corticosteroids were not permitted. Functional ability and the modified Sharp/van der Heijde score were determined after 2 years of therapy.
Results: Of the 120 patients, 67 responders (56%) had persistent low disease activity and discontinued infliximab after a median of 9.9 months, with a median MTX dosage of 10 mg/week after 2 years. Ten other patients experienced a disease flare after discontinuation and resumed infliximab after a median of 3.7 months. Thirteen patients did not achieve persistent low disease activity and received infliximab at various dosages. Treatment was unsuccessful in 30 patients. In the 67 responders, the progression of joint damage was lower than in the 30 patients in whom treatment failed.
Conclusion: Fifty-six percent of patients with active early RA, initially treated with infliximab plus MTX, could discontinue infliximab after achieving a DAS of <or=2.4. Low disease activity was maintained in these patients while the MTX dosage was tapered to 10 mg/week.
Comment in
-
Why publish a secondary analysis of only one treatment group in the Behandelstrategieën voor Reumatoide Artritis trial? Comment on the article by van der Bijl et al.Arthritis Rheum. 2007 Nov;56(11):3876; author reply 2876-7. doi: 10.1002/art.23064. Arthritis Rheum. 2007. PMID: 17968912 No abstract available.
Similar articles
-
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.Ann Rheum Dis. 2007 Oct;66(10):1356-62. doi: 10.1136/ard.2006.066662. Epub 2007 Feb 9. Ann Rheum Dis. 2007. PMID: 17293364 Free PMC article. Clinical Trial.
-
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.Arthritis Rheum. 2005 Apr;52(4):1020-30. doi: 10.1002/art.20982. Arthritis Rheum. 2005. PMID: 15818697 Clinical Trial.
-
Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-77-82. Clin Exp Rheumatol. 2006. PMID: 17083767 Clinical Trial.
-
Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Semin Arthritis Rheum. 2009. PMID: 18823645 Review.
-
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.Rheumatology (Oxford). 2009 Sep;48(9):1114-21. doi: 10.1093/rheumatology/kep155. Epub 2009 Jul 9. Rheumatology (Oxford). 2009. PMID: 19589891 Review.
Cited by
-
Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.Arthritis Res Ther. 2023 Nov 20;25(1):222. doi: 10.1186/s13075-023-03199-0. Arthritis Res Ther. 2023. PMID: 37986101 Free PMC article.
-
A subset of type-II collagen-binding antibodies prevents experimental arthritis by inhibiting FCGR3 signaling in neutrophils.Nat Commun. 2023 Sep 23;14(1):5949. doi: 10.1038/s41467-023-41561-7. Nat Commun. 2023. PMID: 37741824 Free PMC article.
-
Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.Intern Med. 2020;59(16):1963-1970. doi: 10.2169/internalmedicine.3934-19. Epub 2020 Aug 15. Intern Med. 2020. PMID: 32801270 Free PMC article.
-
Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data.Rheumatol Ther. 2020 Jun;7(2):311-325. doi: 10.1007/s40744-020-00198-4. Epub 2020 Feb 29. Rheumatol Ther. 2020. PMID: 32114644 Free PMC article.
-
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.Ann Rheum Dis. 2020 Jan;79(1):94-102. doi: 10.1136/annrheumdis-2019-216169. Epub 2019 Oct 19. Ann Rheum Dis. 2020. PMID: 31630117 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical